Maze Therapeutics, Inc.

NASDAQ: MAZE · Healthcare · Biotechnology

PublicHQ South San Francisco, CA · San MateoCIK 0001842295Reports USD

#303 of 1,418 Healthcare companies by revenue

EA Score

49D

FH 63DQ 26GM —SS 53

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

$20.0M

Rev growth YoY (TTM)

+700.0%

Net income (FY)

-$131.1M

Employees

141

as of 2026-08-09

Market cap

$1.6B

as of 2026-08-09

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$167.5M$167.5M2025

Net income-$131.1M-$131.1M2025

Operating income-$142.9M-$142.9M2025

Total assets$397.1M$397.1M2025

Liabilities$42.2M$42.2M2025

Equity$355.0M$355.0M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Maze Therapeutics, Inc.’s revenue?

Maze Therapeutics, Inc. booked $167.5M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -78.3% net margin.

Peers · Healthcare

Syndax Pharmaceuticals, Inc.52D REGENXBIO Inc.54D Ginkgo Bioworks Holdings, Inc.44D Pacific Biosciences of California, Inc.55C MariMed Inc.66B Liquidia Corporation58C

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Equinix, Inc.$9.2B74B Robinhood Markets, Inc.$4.5B67B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$053D

Key facts

CEOJason Coloma

SectorHealthcare

IndustryBiotechnology

HeadquartersSouth San Francisco, CA

ExchangeNASDAQ: MAZE

Employees141

IPO date2025-01-31

Latest filings

8-K2026-08-17 8-K2026-08-11 10-Q2026-08-11 8-K2026-06-10 8-K2026-05-22 8-K2026-05-12 10-Q2026-05-12 DEF 14A2026-04-28

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.